Last update 26 May 2025

Atogepant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Atogepant (USAN), AGN-241689, MK-2918
+ [5]
Target
Action
antagonists
Mechanism
CGRP antagonists(Calcitonin gene-related peptide antagonists)
Therapeutic Areas
Inactive Indication-
Originator Organization
Inactive Organization
License Organization
Drug Highest PhaseApproved
First Approval Date
United States (28 Sep 2021),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC29H23F6N5O3
InChIKeyQIVUCLWGARAQIO-OLIXTKCUSA-N
CAS Registry1374248-81-3

External Link

KEGGWikiATCDrug Bank
D11313Atogepant-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Migraine Disorders
United States
28 Sep 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Migraine Without AuraPhase 3
Australia
05 Mar 2021
Migraine Without AuraPhase 3
Canada
05 Mar 2021
Migraine Without AuraPhase 3
Denmark
05 Mar 2021
Migraine Without AuraPhase 3
France
05 Mar 2021
Migraine Without AuraPhase 3
Netherlands
05 Mar 2021
Migraine Without AuraPhase 3
Russia
05 Mar 2021
Migraine Without AuraPhase 3
Spain
05 Mar 2021
Migraine Without AuraPhase 3
Sweden
05 Mar 2021
Acute migraineIND Approval
China
25 Dec 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
lzbjkjtjmy(nkfbntlfli) = wmwyzndpnc jvfgxivqbs (uogomqdzpp )
Positive
07 Apr 2025
Placebo
lzbjkjtjmy(nkfbntlfli) = rulifqbqfq jvfgxivqbs (uogomqdzpp )
Phase 1
-
12
vohxdbrpxa(zafiaubzpb) = There were 2 mild adverse events, one abdominal pain upper and one dyspepsia llwrqwjrlp (mzpgnzxayh )
Positive
07 Apr 2025
Phase 2/3
-
Atogepant 60mg once-daily
sjcyijummk(xhdhsblxas) = tzxuxcmoax tyrqjgmkzg (unkisxxdgu )
-
01 Dec 2024
Placebo
itepcyieto(kagltdcbed) = xjetsigdgw haxnppfttd (cjsnytfrtp )
Phase 4
263
(Atogepant 60 mg (Period 1))
ofxazsuuaf = dkfzkwavzr gwdcpzuhcd (ytovzxecqm, gpnbtbcdsv - ihaijqbuls)
-
08 Oct 2024
(Atogepant 60 mg + Ubrogepant 100 mg (Period 2))
ofxazsuuaf = imuumlibxe gwdcpzuhcd (ytovzxecqm, zyvnzfkvcx - qzzffzrvhi)
Phase 3
755
acznwcyelk(bzustdvqln) = hxabkmkctd uinsydasae (eupofhcwpb, -4.0 to -1.5)
Positive
23 Jul 2024
Not Applicable
-
-
ybppkpdoew(mlgewtwpkx) = qmmctkpviv arqactsutn (hndciwgryl )
-
28 Jun 2024
ybppkpdoew(mlgewtwpkx) = caxafjjnrm arqactsutn (hndciwgryl )
Phase 3
Migraine Disorders
calcitonin gene-related peptide receptor
-
vspsytlxhx(geszpdxxlu) = gsbgexhdpj ksunbwyiop (vqyfwmzija )
Positive
21 May 2024
vspsytlxhx(geszpdxxlu) = zretlvuvqg ksunbwyiop (vqyfwmzija )
Phase 3
-
Atogepant 60 mg
caczwdxdko(lkqqxlzydf) = oxialufimm fdwhjqmwdg (wzixyuzpof )
Positive
12 Apr 2024
Not Applicable
Migraine Disorders
calcitonin gene-related peptide
-
owluzpcyta(vqaerbmrfu) = qialvokywm hddlbeviar (lbzitjnmhv )
Negative
09 Apr 2024
CGRP mAbs (eptinezumab, erenumab, fremanezumab, galcanezumab)
owluzpcyta(vqaerbmrfu) = kpmneztrua hddlbeviar (lbzitjnmhv )
Phase 4
Migraine Disorders | Acute migraine
calcitonin gene-related peptide (CGRP) receptor antagonist
263
ocvxvrailh(wkksvoolld) = 8.4% vs 3.2% aokvrkhnjm (txripsvaxz )
Positive
09 Apr 2024
Ubrogepant 100mg PRN
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free